SHARE

The Royal Marsden launches world’s first integrated multiple myeloma pathway

The Royal Marsden has launched MyTrack™ Myeloma, a fully integrated patient pathway for multiple myeloma. Initially available to private patients with Bupa coverage, it enables personalised treatment decisions through precise tumour profiling.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.